Key Takeaways
- Phibro reported third-quarter net sales of $383.5 million, up 10% year over year.
- Adjusted EBITDA increased 11% to $60.8 million.
- Animal Health sales rose 13%, supported by growth in MFAs, nutritional specialties, and vaccines.
- The company increased portions of its fiscal 2026 financial guidance ranges.
- Phibro expanded its revolving credit facility by $125 million to strengthen liquidity and operating flexibility.
- The company recently launched its Sustainable Solutions Platform, including VERRATAIN™ Verified Sustainability Solutions.
- Companion animal and vaccine sales contributed to growth within the Animal Health segment.
Phibro Animal Health Corporation reported third-quarter fiscal 2026 net sales of $383.5 million, an increase of 10% compared to the prior-year period, while also updating its full-year financial guidance.
The company reported net income of $24 million, up 15% year over year, with diluted earnings per share increasing 16% to $0.59. Adjusted EBITDA rose 11% to $60.8 million, while adjusted diluted EPS increased 19% to $0.76.
“Phibro delivered a strong third quarter, with net sales increasing 10% to $383.5 million and adjusted EBITDA rising 11% to $60.8 million,” said Jack Bendheim, chairman, president, and CEO of Phibro Animal Health Corporation. “Results were driven by continued strength in our Animal Health business, where sales increased 13%, supported by robust demand across MFAs, nutritional specialties, and vaccines.”
Animal Health segment sales reached $291.2 million during the quarter, increasing 13% year over year. The company attributed growth to increased sales from its MFA portfolio acquisition, higher demand for nutritional specialty products, stronger companion animal sales, and increased vaccine demand internationally and within the domestic swine market.
Mineral Nutrition sales increased 10% to $73.4 million due to stronger demand for zinc and trace minerals, while Performance Products sales declined 17% as demand weakened in personal care ingredient markets.
Phibro also announced several strategic developments following the quarter, including an expansion of its revolving credit facility by $125 million, increasing total borrowing capacity to $435 million. The company said the move enhances liquidity and operational flexibility.
Additionally, Phibro recently launched its Sustainable Solutions Platform, including the introduction of VERRATAIN™ Verified Sustainability Solutions. The company also referenced a regulatory development in Brazil affecting certain antimicrobial products.
For fiscal year 2026, Phibro updated guidance to project net sales between $1.46 billion and $1.50 billion and adjusted EBITDA between $247 million and $255 million. Adjusted diluted EPS guidance was raised to a range of $2.98 to $3.10.
Information sourced from the company’s earnings release.
